Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc., is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. The Company's lead program, KRSA-028, is a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, it is advancing a pipeline of innovative therapies for neurodegenerative diseases.
Back to dashboard
Company Information
About this company
Key people
Tomas Kiselak
Chairman of the Board
Jonathan Violin
President, Chief Executive Officer, Director
Mark J. Vignola
Chief Financial Officer
Matthew Leoni
Chief Medical Officer
Andrew Gottesdiener
Director
Heidi Henson
Director
Michelle Pernice
Director
Nimish Shah
Director
Click to see more
Key facts
- Shares in issue45.55m
- EPICKRSA
- ISINUS23255M3034
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$21.34m
- Employees1
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.